32 patents currently held
38 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Sep 2037. from the record
Of the 38 now held by other companies, 28 were conveyed to Flagship Pioneering Innovations VI LLC in the filing they arrived in, and 10 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Sep 2037
Next term end
25
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Sep 2037 · Medium confidence
Also notable
Ends Jul 2039 · High confidence
Also notable
Ends Dec 2038 · High confidence
Methods and Compositions for Modulating Gene Expression
US 11,624,065
Cited by 13 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2037.
Compositions for Facilitating Membrane Fusion and Uses Thereof
US 11,576,872
Cited by 24 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2039.
Compositions Comprising Circular Polyribonucleotides and Uses Thereof
US 11,160,822
A family of 11 related applications built on the 2021 grant. Protection runs to 2038.
Formerly held, still cited
Notable
Ends Nov 2035 · High confidence
Cited by 168 later US patents, top 5% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.
now held by Pharmabiome AG
Also notable
Ends Dec 2038 · High confidence
Cited by 8 later US patents, top 25% of utility patents granted in 2021 in our data. Protection runs to 2038.
conveyed to Flagship Pioneering Innovations VI, LLC
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 4, 2027The maintenance fee for Methods and Related Compositions for Manufacturing Food and Feed (US 11,690,387) comes due Jan 4, 2027. Unpaid by Jul 6, 2027, it lapses early.
- 1 fee due Apr 29, 2027The maintenance fee for Methods and Compositions for Treating Cancer Using P2RX2 Inhibitors (US 10,457,740) comes due Apr 29, 2027. Unpaid by Oct 29, 2027, it lapses early.
- 1 fee due May 14, 2027The maintenance fee for Active Agents and Methods of Their Use for the Treatment of Metabolic Disorders and Nonalcoholic Fatty Liver Disease (US 11,813,272) comes due May 14, 2027. Unpaid by Nov 15, 2027, it lapses early.
- 1 fee due Jul 2, 2027The maintenance fee for Methods of Altering a Target Nucleotide Sequence with an RNA-Guided Nuclease and a Single Guide RNA (US 11,859,219) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
- 1 fee due Oct 9, 2027The maintenance fee for Compositions and Methods for Cell Delivery (US 11,951,154) comes due Oct 9, 2027. Unpaid by Apr 10, 2028, it lapses early.
- 1 fee due Nov 7, 2027The maintenance fee for Compositions and Related Methods for Modulating Endosymbionts (US 11,974,574) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.
Recent changes
- Oct 30Assignment recorded on 1 record: Lande-Diner, Laura Gabriela and 1 other to Flagship Pioneering, Inc. Recorded Oct 30, 2026, executed Sep 6, 2017. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76575, frame 211.
- Oct 30Assignment recorded on 1 record: Omega Therapeutics, Inc. to Flagship Pioneering, Inc. Recorded Oct 30, 2026, executed Sep 5, 2017. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76575, frame 311.
What they patent
The 5 largest of its 25 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Methods and Compositions for Modulating Gene Expression | 4 in force | to Dec 2038 |
| Method for Modifying Plants with a Recombinant RNA Molecule | 2 in force | to Oct 2042 |
| Anellovirus Compositions and Methods of Use | 2 in force | to Jun 2039 |
| Active Agents and Methods of Their Use for the Treatment of Metabolic Disorders and Nonalcoholic Fatty Liver Disease | 2 in force | to Jun 2039 |
| Compositions and Methods for Cell Delivery | 2 in force | to Nov 2037 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,624,065 | Methods and Compositions for Modulating Gene Expression In force · Medium confidence | In force | Medium confidence | |
| US 11,382,950 | Compositions and Methods for Cell Delivery In force · High confidence | In force | High confidence | |
| US 11,951,154 | Compositions and Methods for Cell Delivery In force · High confidence | In force | High confidence | |
| US 12,171,801 | Compositions and Related Methods for Controlling Vector-Borne Diseases In force · Medium confidence | In force | Medium confidence | |
| US 11,859,219 | Methods of Altering a Target Nucleotide Sequence with an RNA-Guided Nuclease and a Single Guide RNA In force · High confidence | In force | High confidence | |
| US 12,018,049 | Compositions and Related Methods for Controlling Vector-Borne Diseases In force · High confidence | In force | High confidence | |
| US 12,209,246 | Methods of Genetically Altering a Whole Plant Seed In force · High confidence | In force | High confidence | |
| US 10,457,740 | Methods and Compositions for Treating Cancer Using P2RX2 Inhibitors In force · High confidence | In force | High confidence | |
| US 11,312,955 | Methods and Compositions for Modulating Gene Expression In force · Medium confidence | In force | Medium confidence | |
| US 12,509,683 | Methods and Compositions for Modulating Gene Expression In force · Low confidence | In force | Low confidence |
Also on record, not counted in the 32: 38 patents in force now held by others · 6 patents ended · 157 applications pending · 63 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.